Abstracts tagged "anti-TNF therapy"

Abstract Number: 077 • 2020 Pediatric Rheumatology Symposium
Tubulointerstitial Nephritis and Uveitis (TINU): A Pediatric Case Series with Longitudinal Followup
Deborah Stein ¹, Elizabeth Benoit ¹ and Mindy Lo¹, ¹Boston Children's Hospital, Boston
Background/Purpose: Tubulointerstitial nephritis and uveitis (TINU) syndrome is an uncommon condition that is likely under-recognized. The ideal treatment of both renal and ophthalmologic disease activity…
Abstract Number: 101 • 2020 Pediatric Rheumatology Symposium
Uveitis Treatment in the CARRA II Registry: Tumor Necrosis Factor-inhibitors and Beyond
Mona Riskalla¹, Fatima Barbar-Smiley ², Michael Shyne ¹ and Melissa Lerman ³, ¹University of Minnesota, Minneapolis, Minnesota, ²Nationwide Children's Hospital, Columbus, Ohio, ³Philadelphia, Pennsylvania
Background/Purpose: Uveitis associated with JIA (JIA-U) is the most common extra-articular complication of JIA. As JIA-U is associated with significant risk of visual loss and…
Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Sarah Kodama¹, Deepti Gupta ², Erin Sullivan ³ and Yongdong Zhao ⁴, ¹School of Medicine, Virginia Commonwealth University, Richmond, ²Pediatric Dermatology, School of Medicine, University of Washington, Seattle, ³Seattle Children's Research Institute, Seattle, ⁴University of Washington, Seattle
Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…
Abstract Number: 29 • 2019 ACR/ARP Annual Meeting
Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro
Bohdan Harvey¹ and Zehra Kaymakcalan ¹, ¹AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Therapeutic anti-TNF biologic agents can be distinct in their structure and/or in their binding to TNF. Whether these differences affect the functional properties of…
Abstract Number: 988 • 2019 ACR/ARP Annual Meeting
Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis
Bradley Hooker¹, Xiaomeng Zhang ², Todd Cole ², Ann Tovcimak ², Shaughn Bryant ³, Lucy Phillips ³, David Blanchard ², Dustin Wooten ², Qi Guo ², Melanie Ruzek ³, Adrian Hobson ³, Michael McPherson ³, Robert Stoffel ³, Wendy Waegell ³ and Yanping Luo ², ¹AbbVie, North Chicago, IL, ²AbbVie, North Chicago, ³AbbVie, Worcester
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory joint disease of autoimmune etiology. If insufficiently treated, RA leads to joint damage and irreversible disability. Although there…
Abstract Number: 2273 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Offspring According to TNFi Subtypes
Evelyne Vinet¹, Yvan St-Pierre ¹, Cristiano S. Moura ¹, Jeffrey Curtis ² and Sasha Bernatsky ³, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: TNFi subtypes have differential placental transfer, with some reaching higher fetal than maternal blood levels. Thus, certain TNFi subtypes could cause immunosuppression in the offspring.…
Abstract Number: 94 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells
Shotaro kawano¹, Hiroki Mitoma ², Shoichiro Inokuchi ³, Masahiro Ayano ², Yasutaka Kimoto ⁴, Mitsuteru Akahoshi ², Yojiro Arinobu ², Koichi Akashi ², Takahiko Horiuchi ⁵ and Hiroaki Niiro ⁶, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, ³Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Fukuoka, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁶Clinical Education Centre, Kyushu University Hospital, Fukuoka, Japan, Fukuoka, Japan
Background/Purpose: Tumor Necrosis Factor (TNF) α is a multifunctional cytokine with pro-inflammatory and anti-inflammatory characteristics. Regulatory T cells (Treg) express a remarkably high level of…
Abstract Number: 990 • 2019 ACR/ARP Annual Meeting
Development of a Novel Anti TNF-Steroid Antibody Drug Conjugate That Shows Promising Efficacy at Doses That Avoid Steroid Side Effects in a Mouse Model of Rheumatoid Arthritis
Wendy Waegell¹, Christian Goess ², Robert Stoffel ¹, Michael McPherson ¹, Adrian Hobson ¹, Suzanne Mathieu ², Lucy Phillips ¹ and Shaughn Bryant ¹, ¹AbbVie, Worcester, ²Abbvie bioresearch Center, Worcester, MA
Background/Purpose: TNF-inhibitors are a well established therapy for autoimmune diseases including rheumatoid arthritis, Crohn’s disease, psoriasis and ankylosing spondylitis but they have limited efficacy in…
Abstract Number: 2292 • 2019 ACR/ARP Annual Meeting
Disease Flares of Rheumatoid Arthritis During Pregnancy: What Is the Impact of Stopping bDMARDs at the Beginning of Pregnancy?
Maria Chiara Gerardi¹, Laura Andreoli ¹, Antía García-Fernández ², Chiara Bazzani ³, MATTEO FILIPPINI ³, MICAELA FREDI ¹, ROBERTO GORLA ³, Maria Grazia Lazzaroni ⁴, Cecilia Nalli ³, MARCO TAGLIETTI ⁵, SONIA ZATTI ⁶, ANDREA LOJACONO ⁶, Franco Franceschini ¹ and Angela Tincani ¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ²Ramon y Cajal University Hospital, Madrid, Spain, Madrid, Madrid, Spain, ³Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ⁴Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy., Brescia, Italy, ⁵[email protected], Brescia, Italy, ⁶Obstetrics and Gynaecology, Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: During pregnancy, patients with rheumatoid arthritis (RA) can experience flares that might influence pregnancy outcomes. We aimed at assessing disease course during pregnancy and…
Abstract Number: 377 • 2019 ACR/ARP Annual Meeting
Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition
Matthew Baker¹, Khushboo Sheth ¹, Julia Simard ², Stanford Shoor ¹ and Mark Genovese ³, ¹Stanford University, Palo Alto, CA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by the presence of noncaseating granulomas. When it affects the myocardium, it can result in electrical conduction…
Abstract Number: 1242 • 2019 ACR/ARP Annual Meeting
Impact of Smoking Status on Remission in Hidradenitis Suppurativa
Amil Agarwal ¹, Marissa Mangini ¹, Derek Jones ¹, Catherine Hood ¹, Richard Amdur ¹ and Victoria Shanmugam², ¹The George Washington University School of Medicine and Health Sciences, Washington, DC, ²George Washington University, Georgetown, DC
Background/Purpose: Hidradenitis Suppurativa (HS) is an inflammatory disease of the apocrine sweat glands characterized by recurrent abscessing inflammation. The molecular drivers of HS are poorly…
Abstract Number: 2297 • 2019 ACR/ARP Annual Meeting
Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System
Yiyi Luo ¹, Andrea Pluma ², Raul Castellanos-Moreira³, Estefania Moreno ⁴, Nuria Baños ⁵, Sebastian DC Rodriguez-Garcia ⁶, Angela Deyà-Martínez ¹, Ana Pilar Garcia-Garcia ¹, Mireia Torres ⁷, Dolors Grados ⁸, Manel Casellas ⁹, Manel Juan ¹, Ana Esteve-Sole ¹ and Laia Alsina ¹⁰, ¹Immunology Department. Center for Biomedical Diagnosis. Hospital Clínic of Barcelona IDIBAPS. Barcelona University. Barcelona. Functional unit of Clinical Immunology HSJD-HCP.Universidad de Barcelona. Pediatric Investigation Institute SJD, Barcelona, Spain, ²Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁴Rheumatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, ⁵Matern-Infantile Department, Hospital Clínic of Barcelona. Barcelona. Spain, Barcelona, Spain, ⁶Arthritis Unit. Rheumatology Department. Hospital Clinic of Barcelona. Barcelona. Spain, Barcelona, Spain, ⁷Neonatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, ⁸Hospital d'Igualada, Barcelona, ⁹Hospital Universitari Vall d'Hebron, Barcelona, ¹⁰Hospital Sant Joan de Déu, Barcelona, Spain
Background/Purpose: Up to half of pregnant patients with rheumatic diseases experience disease activity which can increase the risk of pregnancy complications and poor disease outcomes. Treatment…
Abstract Number: 419 • 2019 ACR/ARP Annual Meeting
Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
Panagiotis Athanassiou ¹, Ioannis Kallitsakis ², Gkikas Katsifis ³, Anastasios Kotrotsios ⁴, Georgios Vosvotekas ⁵, Panagiotis Georgiou ⁶, Andreas Bounas ⁷, Yiannis Haratsis ⁸, Evangelia Petrikkou ⁸ and Dimitrios Vassilopoulos⁹, ¹General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ²Private Practice, Chania, Greece, ³Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, ⁴Private Practice, Karditsa, Greece, ⁵Euromedica General Clinic of Thessaloniki, Rheumatology Clinic, Thessaloniki, Greece, ⁶General Hospital of Patras “Agios Andreas”, Patras, Greece, ⁷Olympion therapeutirion, Patras, Greece, ⁸Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial S.A, Medical Affairs, Athens, Greece, ⁹2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece
Background/Purpose: There are limited real life data regarding the effect of golimumab on work productivity and activity impairment in rheumatic diseases. The aim of our…
Abstract Number: 1397 • 2019 ACR/ARP Annual Meeting
Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Clinical studies have demonstrated the efficacy of tocilizumab (TCZ) administered with methotrexate (MTX) in improving rheumatoid arthritis (RA) disease activity in patients who have…
Abstract Number: 2359 • 2019 ACR/ARP Annual Meeting
High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis
Ori Elkayam ¹, Merav Lidar ², Tatiana Reitblat ³, Devy Zisman ⁴, Alexandra Balbir-Gurman ⁵, Odelia Kakakian ¹, Tanya Meshiach ⁵, Ronit Almog ⁶ and Ofir Elalouf¹, ¹Tel Aviv Medical Center, Tel Aviv, Israel, ²Rheumatology Unit Sheba Medical Center, Ramat Gan, Israel, ³Barzilai Medical Center, Ashkelon, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Rambam Medical Center, Haifa, Israel, ⁶the7Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel
Background/Purpose: The primary objective was to evaluate the effect of body mass index (BMI) on tumor necrosis factor α (TNF-α) blockers (including etanercept, infliximab, adalimumab…

1
2
3
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].